UCB Farchim SA - Edelweiss

Project Overview

Exyte*, as EPCMV partner for UCB, has designed and built one of the largest biotech production facilities in Europe within 28 months. Two years after the successful hand-over, Exyte supported UCB again for the production capacity increase for Cimzia™ to 1,000 kg/year.

UCB’s new greenfield facility for antibody production against rheumatoid arthritis is the main production center for Cimzia™. It is fitted with ultra-modern laboratories and a highly automated production line. One of the main challenges was the ambitious schedule, aiming to fast-track finalization in 28 months from conceptual design to operational qualification.

Design Highlights

The project placed high emphasis on a low environmental footprint and strong sustainability goals, paired with full ASTM2500 implementation. Edelweiss has been one of the largest biotech projects in Europe for many years. Another highlight is the lean approach, with a clear focus on value and value flow throughout the entire project.

*This work was completed by Pharmaplan, now part of Exyte